What LL-37 is
LL-37 is an endogenous antimicrobial peptide involved in innate immune defense, barrier function, and wound-related signaling.
LL-37 is grouped under Fitness + Recovery / Endogenous / Biology on PeptideFactCheck because it attracts interest because it sits at the intersection of immune defense, wound context, and skin biology.
The useful starting point is to separate the molecule itself from the internet story around it. It attracts interest because it sits at the intersection of immune defense, wound context, and skin biology.
Why people keep looking it up
It attracts interest because it sits at the intersection of immune defense, wound context, and skin biology.
LL-37 is an endogenous antimicrobial peptide involved in innate immune defense, barrier function, and wound-related signaling.
LL-37 tends to stay in the conversation because it touches a familiar public theme: antimicrobial peptide, innate immunity, and wound context. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Real endogenous peptide biology plus limited clinical work, but claims still need careful boundaries.
Human biology and some clinical investigation exist, but product-level therapeutic claims are still much narrower than internet language suggests.
Preclinical work explores antimicrobial activity, immune modulation, and tissue-response signaling.
Why this page carries the current tier: Real endogenous peptide biology plus limited clinical work, but claims still need careful boundaries.
The current seed trail for LL-37 is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
Manipulating innate immune peptides can be biologically consequential and should not be reduced to a simple recovery hack.
Endogenous biology should be kept separate from any unapproved commercial peptide product.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for LL-37. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for LL-37 is CID 16198951. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16198951
- Formula
- C205H340N60O53
- Molecular weight
- 4493
- InChIKey
- POIUWJQBRNEFGX-XAMSXPGMSA-N
Matched synonyms include LL-37, ropocamptide, Cap-18, cathelicidin LL-37, CAP18, Antibacterial peptide LL-37, antimicrobial peptide LL-37, LL-37 antibacterial peptide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for LL-37 returns 20 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for LL-37 returns 2461 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.